MUNDIPHARMA
16.1.2020 15:00:04 CET | Business Wire | Press release
Mundipharma today announced a partnership with Samsung Bioepis to commercialize Samsung Bioepis’ first-wave biosimilar candidates in Taiwan and Hong Kong.
The partnership covers Samsung Bioepis’ biosimilar candidates in the field of immunology and oncology, including SB5 (adalimumab), SB4 (etanercept), SB3 (trastuzumab), and SB8 (bevacizumab).
Through the partnership, Mundipharma will be the exclusive commercialization partner, while Samsung Bioepis will remain the Marketing Authorisation Holder (MAH), responsible for clinical development, regulatory registration, and manufacture of the biosimilars.
“This partnership brings together Samsung Bioepis’ proven biosimilar development platform with Mundipharma’s commercial acumen and market insight and ability to increase patient access to proven treatments,” said Mundipharma CEO, Raman Singh. “This partnership will help to address the patient need in two important territories in Asia for immunology and oncology treatments,” he added.
About Mundipharma
Mundipharma’s independent associated companies are privately owned entities covering the world’s pharmaceutical markets. Mundipharma is a prime example of a company that consistently delivers high quality products while standing by the values that represent the company. Our mission is to alleviate the suffering of patients with cancer and non-cancer pain and to substantially improve their quality of life. Mundipharma is dedicated to bringing to patients with severe and debilitating diseases the benefit of novel treatment options in fields such as pain, oncology, oncology supportive care, ophthalmology, respiratory disease and consumer healthcare. For more information please visit: www.mundipharma.com.sg .
About Samsung Bioepis Co., Ltd.
Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology and hematology. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com and follow us on social media – Twitter , LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200116005483/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HJS Foundation Releases JEP Protocol & HJS Framework: The "Black Box" for AI, Enabling Verifiable Human Oversight24.3.2026 04:36:00 CET | Press release
HJS Foundation (Human Judgment Systems Foundation) today released two complementary solutions: the Judgment Event Protocol (JEP) and the Human Judgment Structure (HJS) framework. As a minimalist open standard, JEP generates tamper-proof records of AI decision accountability, just like an aircraft black box; HJS embeds human judgment logic into AI operation processes — together, they transform "human oversight" from a regulatory requirement into a verifiable technical fact, providing an optional technical solution for AI accountability. How to prove that AI decisions (such as loan approvals, medical diagnoses, border screenings, etc.) have undergone human review? JEP generates immutable audit trails of human intervention through four cryptographic primitives — Judge, Verify, Delegate, Terminate; HJS builds a controllable and accountable system to prevent risks such as AI drift and ensure that human judgment guides AI operations. Current systems rely on alterable post-hoc documentation,
Power Integrations Extends Flyback Topology to Enable 440 W, Offering Simpler Alternatives to Resonant Power Designs23.3.2026 22:45:00 CET | Press release
New TOPSwitchGaN ICs more than double power output, reducing system cost, complexity, and design time APEC 2026 – Power Integrations (NASDAQ: POWI), the leader in high-voltage integrated circuits for energy-efficient power conversion, today introduced a breakthrough in flyback topology extending the power range of flyback converters to 440 W—well beyond the limits that traditionally required more complex resonant and LLC topologies. The new TOPSwitchGaN™ flyback IC family unites the company’s groundbreaking PowiGaN™ technology with its iconic TOPSwitch™ IC architecture, reducing complexity, eliminating heat sinks in many cases, shortening design time, improving manufacturability, and lowering total system cost. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323686299/en/ The new TOPSwitchGaN™ flyback IC family extends the power range of flyback converters to 440 W—well beyond the limits that traditionally required more co
I-Pulse Announces Strategic Partnership to Advance Geothermal Pulsed Power Applications in the Millungera Basin, Australia23.3.2026 22:40:00 CET | Press release
I-Pulse to assume operational control of Millungera Basin Geothermal Project with Sunrise Energy Metals, Greenvale Mining Millungera Basin Total Identified Stored Energy Estimated to Exceed 611,000 Petajoules, or 600x Australia’s Current Annual Electricity Consumption I-Pulse’s G-Pulse Tool Deploys High Pulsed Power to Unlock Access to Geothermal Energy I-Pulse Co-Founder, Chairman, and CEO Robert Friedland, I-Pulse Co-Founder and Head of Technology Laurent Frescaline, and Sunrise Energy Metals Managing Director Sam Riggall, are delighted to announce a partnership to deploy and validate I-Pulse’s G-Pulse pulsed power drilling technology in the Millungera Basin, a large-scale geothermal clean energy resource located in northwest Queensland, Australia. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323421297/en/ Left: Millungera Basin location in Queensland, Australia. Right: Millungera Basin (in brown) to the east of the M
The Estée Lauder Companies’ Statement on Potential Transaction with Puig23.3.2026 21:15:00 CET | Press release
The Estée Lauder Companies Inc. (NYSE: EL) confirms that it is in discussions regarding a potential business combination with Puig, in which the two companies would potentially merge their businesses. No final decision has been made, and no agreement has been reached. Unless and until an agreement is signed between the companies, there can be no assurances regarding the deal or its terms. Forward-Looking Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding a potential transaction and the anticipated timing, terms, and completion of any such transaction. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, among others, the possibility that no agreement will be reached, tha
Kinaxis Recognized as a Leader in the 2026 Gartner® Magic Quadrant™ Reports for Supply Chain Planning23.3.2026 19:12:00 CET | Press release
Recognition based on company’s Completeness of Vision and Ability to Execute Kinaxis® Inc. (TSX: KXS), a global leader in supply chain orchestration, today announced it has been positioned as a Leader in both the 2026 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions for Discrete Industries and the 2026 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions for Process Industries. In both reports, Gartner recognized Kinaxis for its ability to execute and completeness of vision. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260323129357/en/ Kinaxis Recognized as a Leader in the 2026 Gartner® Magic Quadrant™ Reports for Supply Chain Planning: Discrete Industries Kinaxis has been recognized as a Leader in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions for eleven times in a row. Kinaxis has also been recognized as a Leader in the 2026 Gartner Magic Quadrant for Supply Chain Planning Solutions
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom